The difference between groups is statistically significant (HR = 0.73, 95%CI:0.69∼0.77, p < 0.00001), it suggests that the efficacy of PD-1/PD-L1 in the treatment of NSCLC is better than docetaxel chemotherapy (Figure 3 Comparison of overall survival between groups). Here, PDCD1 is linked to non-small cell lung carcinoma.